Genetic Basis and Novel Treatment Strategies in Parkinson's Disease – A Review
Keywords:Parkinson's disease, Neurodegenerative disorder, Synuclein alpha, Autophagy
Parkinson's disease (PD) is the 2nd most common progressive neurodegenerative disorder after Alzheimer's disease. Approximately 60000 are diagnosed with Parkinson's disease each year and more than 10 million people are living with PD. PD is a neurodegenerative disorder in addition to the causes of PD are so many, it's not caused by a single pathophysiologic disturbance. So many drugs are available to treat PD but all are only for symptomatic relief no one drug is a disease-modifying agent. Although so many targets are available for targeting the Synuclein alpha, mitochondrial oxidative stress, autophagy, targeting glial cell inflammation, targeting metal ion homeostasis. But till now no one drug is successful in targeting these targets. In this review, we have summarized the genetic basis and novel targets available for the disease-modifying strategy for PD.
How to Cite
Copyright (c) 2021 Machhindra D. Bochare and Nagare Santosh Gangadhar
This work is licensed under a Creative Commons Attribution 4.0 International License.